Life sciences news

  • reMYND identifies novel target and small molecules with potential to halt and reverse disease progression in Huntington’s disease through oral administration

    Wednesday August 31st 2022

  • Celyad Oncology announces FDA lifts clinical hold of CYAD-101-002 Phase 1b trial

    Monday August 1st 2022

  • Sequana Medical completes enrollment in Phase 2a SAHARA I DSR study and reports disease-modifying profile for Short Term DSR

    Tuesday July 19th 2022

  • ANeuroTech receives positive feedback from the FDA for its pivotal Phase IIIb development programme for ANT-01 as an adjunctive anti-depression drug for Major Depressive Disorder

    Tuesday July 5th 2022

  • MRM Health starts clinical trial with next-generation optimized consortium therapeutic MH002 in Pouchitis

    Tuesday June 28th 2022

  • UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis

    Tuesday May 10th 2022

  • Oxurion announces top-line results from Part A of Phase 2 INTEGRAL trial evaluating THR-687 for treatment of diabetic macular edema (DME)

    Monday May 9th 2022

  • argenx announces positive Phase 3 data from ADVANCE trial of VYVGART® (efgartigimod alfa-fcab) in adults with primary immune thrombocytopenia

    Thursday May 5th 2022

  • Your news here?

  • reMYND’s novel Alzheimer program reports excellent brain exposure and safety profile in Phase 1; transitioning into Phase 2a

    Tuesday May 3rd 2022

  • Mithra announces improved consolidated topline results from Donesta® Phase 3 studies and launch of recruitment for the extension of European study

    Thursday April 14th 2022

  • Sequana Medical announces the completion of alfapump implantations in POSEIDON, the North American pivotal alfapump study

    Tuesday April 5th 2022

More info?

Contact us

Ellen Telleir

Communication Coordinator

Strategic Partners